AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03960593 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the influence of geriatric factors
Description: Follow-up of patients> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
Study NCT00792922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of community coverage rate
Study NCT00792922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is >5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
Study NCT03389659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: vitamin D3 400IU\*5pills po. qd continue to disease progression
Study NCT03389659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 5 pills po. qd continue to disease progression
Study NCT02246309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embryoscope Time Lapse System
Description: The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
Study NCT02246309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Embryo Culture
Description: Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
Study NCT01881724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep education
Study NCT04134949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: consists of eight weekly treatment sessions of 45 to 60 minutes.
Study NCT04134949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: consists of eight weekly treatment sessions of 45 to 60 minutes.
Study NCT03618433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study group
Description: The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
Study NCT03618433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
Study NCT03773016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art apps
Description: Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
Study NCT03106389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
Study NCT00878189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: 10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
Study NCT03106389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
Study NCT03106389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Misoprostol/Transcervical catheter
Description: Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
Study NCT03031418 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ExoDx Prostate Intelliscore
Description: ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
Study NCT02376816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MCK.micro-Dystrophin
Description: Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter.
Study NCT01315327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Omega-3 fatty acids (derived from fish oil)
Study NCT01315327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Placebo
Study NCT02593110 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Treadmill Exercise Therapy
Description: Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
Study NCT00780676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100 mg tablet by mouth daily
Study NCT00624416 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone synthetic cortisone and Isoproterenol together
Description: Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
Study NCT00755469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-conditioning
Description: The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
Study NCT02593110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
Study NCT02593110 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No exercise control group
Description: Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
Study NCT02593110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise control group
Description: Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
Study NCT02593110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02593110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01235481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise DVD
Description: Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
Study NCT01235481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care during maintenance phase post pulmonary rehabilitation
Study NCT01235481 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care during maintenance phase post pulmonary rehabilitation
Study NCT00687609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
Study NCT02654418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)
Study NCT02654418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)
Study NCT04638842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention Grief COVID-19
Description: The online Intervention Grief COVID-19 aims to provide to the target population a self-applied intervention based on Cognitive Behavioral Therapy, Mindfulness, Behavioral Activation Therapy, and Positive Psychology, aimed at the Psychoeducation regarding the manifestations of normal grief, advice and guidance on how to find emotional relief, with the aim that survivors allow themselves to validate their experience of emotional pain and recognize it as a normal part of their process of adaptation to loss, what does grief deprived of rights consist of, specifically from the contingency of COVID-19, establish self-care measures for people in different areas of their life (physical, emotional, cognitive and spiritual), direct the survivor to relocate the died in his life without his memory causing suffering, in addition to beginning to resume his life project, adjusting according to his needs and goals. The sessions will be delivered in a frequency of one session every three days.
Study NCT00276627 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: communication lecture
Description: lecture on communication skills with oncology patients
Study NCT00276627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lecture plus CD-ROM
Description: Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
Study NCT04348045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A - Olaparib
Description: 300 mg orally twice daily, for a total daily dose of 600mg~Study treatment can be dose-reduced to :~First step : 250 mg twice daily , for a total daily dose of 500 mg Second step: 200 mg twice daily taken twice daily, for a total daily dose of 400 mg No further dose reduction is allowed, and study treatment should be discontinued.
Study NCT04348045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B - durvalumab plus selumetinib
Description: Durvalumab administered IV at a flat dose of 1500 mg on day 1 of every 28-day cycle, Selumetinib Starting Dose : 75 mg twice daily~Study treatment can be dose-reduced to :~Dose Level -1 : 75 mg once daily Dose Level -2 : 50 mg twice daily Dose Level -3 : 50 mg once daily
Study NCT04348045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM C FOLFIRI
Description: FOLFIRI every two weeks Irinotecan 180 mg/m2 Intravenous (IV) on day 1 Folinic acid 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 and 2, and 46h IV infusion of 5-FU 2400 mg/m2
Study NCT00901797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Bankart repair
Description: Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
Study NCT00901797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ABR+ARIC
Description: Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
Study NCT04220437 — intervention group
Intervention type: OTHER
Intervention: no interventin
Description: Our stusy analysed the images obtained from ISR patients, no extra intervention was given based on this study.
Study NCT02124772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib was administered orally, once daily. It was available in tablets (0.125 mg, 0.5 mg, 2 mg dose) as well as in powder form for oral solution (0.05 mg/mL dose).
Study NCT00780676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 75 mg by mouth twice daily.
Study NCT00539955 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Batterer Intervention
Description: Standard state-mandated batterer intervention program (40 hours)
Study NCT00539955 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Alcohol Intervention
Description: Brief alcohol intervention combined with state mandated batterer intervention program
Study NCT04450147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi/Qigong vs. Walking/Stretching
Description: Both interventions can be thought of as a form of movement and exercise.
Study NCT00507754 — intervention group
Intervention type: OTHER
Intervention: T-SPOT TB test
Description: Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
Study NCT04322253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY 1067197)
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
Study NCT03704454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 mg PYC and then placebo
Description: 4 weeks on PYC, then 4 weeks on placebo
Study NCT03704454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100 mg PYC and then placebo
Description: 4 weeks on PYC, then 4 weeks on placebo
Study NCT03704454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and then 50 mg PYC
Description: 4 weeks on placebo, then 4 weeks on PYC
Study NCT03704454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo and then 100 mg PYC
Description: 4 weeks on placebo, then 4 weeks of PYC
Study NCT04213365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.
Description: 12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
Study NCT00869063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Patch
Description: Topical 1% diclofenac sodium patch, applied once daily for 7 days
Study NCT00869063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
Study NCT04565535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novel donor lifestyle optimisation protocol
Description: Diet based on calorie requirement as calculated by indirect calorimetry. Daily exercise.
Study NCT02946008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Delivered over 5 treatment sessions for approximately 1.5 weeks total.
Study NCT02946008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
Study NCT02599727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
Study NCT02599727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
Study NCT02959736 — intervention group
Intervention type: BEHAVIORAL
Intervention: MATADOC and CRS-R
Description: Behavioural assessments for Disorders of Consciousness
Study NCT01392079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
Study NCT03958461 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anti-infective treatment of periodontal pockets
Description: Removing calculi from teeths' periodontal pockets
Study NCT02138552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octenidine dihydrochloride
Description: Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
Study NCT03683641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: Use ESWT on chronic insertional Achilles tendinopathy
Study NCT03683641 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control group
Description: Use sham ESWT on chronic insertional Achilles tendinopathy
Study NCT02823340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional microneedle RF(United, Peninsula Medical, China)
Study NCT01829711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Study NCT01829711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Bag Protectant for Moxetumomab pasudotox
Study NCT01228565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy + Erbitux® + placebo
Description: 3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
Study NCT01228565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy+Erbitux+OTD70DERM
Description: 3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
Study NCT02504762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
Study NCT02504762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
Study NCT03477084 — intervention group
Intervention type: BIOLOGICAL
Intervention: ESBL-producing enterobacteriaceae carriage
Description: Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
Study NCT02695784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Continuation
Description: This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
Study NCT01941498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wavelight® Refractive Suite
Description: Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
Study NCT01941498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK surgery
Description: Surgical procedure for treating refractive error based on corneal reshaping
Study NCT00658879 — intervention group
Intervention type: DRUG
Intervention: Somavert (Pegvisomant)
Description: Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration.